Skip to main content

U.S. flag An official website of the United States government

Animal and Plant Health Inspection Service
U.S. Department of Agriculture

USDA Issues Second Request for Proposals for Highly Pathogenic Avian Influenza Vaccine

This is an archive page.  The links in this content are no longer being updated.

Agency Continues to Prepare for the Potential Return of this Disease

November 20, 2015 -- The United States Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) continues to prepare for the potential return of highly pathogenic avian influenza (HPAI).  APHIS is issuing its second request for proposals (RFP) for vaccine manufacturers with the interest and capability to supply a variety of EA H5 vaccines in sufficient numbers to add to the emergency stockpile. 

APHIS has not approved the use of vaccine to respond to HPAI to date; however, the Agency is preparing to ensure that vaccine is available should the decision be made to use it. Any decision to use vaccination in a future HPAI outbreak would require careful consideration of the efficacy of the vaccine, any impacts of using HPAI vaccine in the field, and the potential trade impacts.  In response to the first RFP issued in August, APHIS awarded contracts for doses of two vaccines for the Eurasian H5 (EA H5) virus strain, which became part of the National Veterinary Stockpile.

Vaccines will be carefully evaluated on a number of factors including their efficacy against EA H5 viruses, and products must meet all of APHIS’ safety, potency, and purity standards.  All eligible products to be considered must be either conditionally or fully licensed or permitted at the time of submission.  Vaccine manufacturers will be evaluated on their ability to produce such vaccines in a timely manner in adequate numbers to meet the needs of the response. 

The RFP is available here.

Although no decision has been made to use vaccine in the event of a future HPAI outbreak, APHIS will continue to issue RFPs for vaccine manufacturers on a quarterly basis through September 2016, to allow additional products to be developed and considered for the stockpile should an HPAI outbreak occur. 


Complementary Content